Manulife (Manufacturers Life Insurance)
NBIX icon

Manulife (Manufacturers Life Insurance)’s Neurocrine Biosciences NBIX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
63,784
-4,328
-6% -$642K 0.01% 863
2026
Q1 		$8.97M Sell
68,112
-23,498
-26% -$3.12M 0.01% 899
2025
Q4 		$13M Sell
91,610
-19,690
-18% -$2.85M 0.01% 769
2025
Q3 		$15.6M Sell
111,300
-1,427
-1% -$193K 0.01% 700
2025
Q2 		$14.2M Buy
112,727
+201
+0.2% +$23.1K 0.01% 707
2025
Q1 		$12.4M Buy
112,526
+2,217
+2% +$281K 0.01% 749
2024
Q4 		$15.1M Sell
110,309
-6,943
-6% -$859K 0.01% 714
2024
Q3 		$13.5M Sell
117,252
-8,149
-6% -$1.12M 0.01% 758
2024
Q2 		$17.3M Buy
125,401
+1,074
+0.9% +$147K 0.02% 652
2024
Q1 		$17.1M Buy
124,327
+7,372
+6% +$1.01M 0.02% 669
2023
Q4 		$15.4M Buy
116,955
+18,070
+18% +$2.08M 0.01% 697
2023
Q3 		$11.1M Buy
98,885
+4,345
+5% +$458K 0.01% 764
2023
Q2 		$8.92M Sell
94,540
-3,724
-4% -$364K 0.01% 838
2023
Q1 		$9.95M Sell
98,264
-2,853
-3% -$297K 0.01% 801
2022
Q4 		$12.1M Sell
101,117
-1,290
-1% -$151K 0.01% 733
2022
Q3 		$10.8M Buy
102,407
+728
+0.7% +$73.9K 0.01% 764
2022
Q2 		$9.93M Buy
101,679
+1,768
+2% +$163K 0.01% 827
2022
Q1 		$9.34M Sell
99,911
-7,233
-7% -$613K 0.01% 930
2021
Q4 		$9.12K Sell
107,144
-1,843
-2% -$170K 0.01% 984
2021
Q3 		$10.5M Buy
108,987
+5,465
+5% +$516K 0.01% 910
2021
Q2 		$10.1M Sell
103,522
-7,037
-6% -$674K 0.01% 961
2021
Q1 		$10.8M Buy
+110,559
New +$11.6M 0.01% 916
2020
Q3 		– Sell
-1,931
Closed -$242K – 2927
2020
Q2 		$242K Buy
+1,931
New +$213K ﹤0.01% 2395
2020
Q1 		– Sell
-2,290
Closed -$246K – 2872
2019
Q4 		$246K Sell
2,290
-85
-4% -$8.9K ﹤0.01% 2458
2019
Q3 		$214K Sell
2,375
-114
-5% -$10.7K ﹤0.01% 2540
2019
Q2 		$210K Buy
+2,489
New +$204K ﹤0.01% 2615
2018
Q4 		– Sell
-2,209
Closed -$272K – 2716
2018
Q3 		$272K Sell
2,209
-302
-12% -$34.3K ﹤0.01% 2584
2018
Q2 		$247K Sell
2,511
-13
-0.5% -$1.16K ﹤0.01% 2951
2018
Q1 		$209K Sell
2,524
-117
-4% -$9.88K ﹤0.01% 2988
2017
Q4 		$205K Sell
2,641
-75
-3% -$5.12K ﹤0.01% 2979
2017
Q3 		$167K Buy
2,716
+51
+2% +$2.69K ﹤0.01% 3118
2017
Q2 		$123K Buy
2,665
+193
+8% +$9.36K ﹤0.01% 3299
2017
Q1 		$107K Sell
2,472
-18
-0.7% -$771 ﹤0.01% 3159
2016
Q4 		$97K Sell
2,490
-20
-0.8% -$905 ﹤0.01% 3236
2016
Q3 		$127K Buy
2,510
+141
+6% +$7.02K ﹤0.01% 3087
2016
Q2 		$108K Sell
2,369
-123,361
-98% -$5.68M ﹤0.01% 3184
2016
Q1 		$4.67M Buy
125,730
+810
+0.6% +$32.1K ﹤0.01% 1072
2015
Q4 		$7.07K Sell
124,920
-7,207
-5% -$366K 0.01% 848
2015
Q3 		$5.26K Buy
132,127
+78,541
+147% +$3.8M 0.01% 988
2015
Q2 		$2.56K Buy
53,586
+759
+1% +$32.2K ﹤0.01% 1345
2015
Q1 		$2.1K Buy
52,827
+4,863
+10% +$174K ﹤0.01% 1385
2014
Q4 		$1.07K Sell
47,964
-1,119
-2% -$21.2K ﹤0.01% 1544
2014
Q3 		$770 Buy
49,083
+1,041
+2% +$15.6K ﹤0.01% 1726
2014
Q2 		$712K Sell
48,042
-2,185
-4% -$30.8K ﹤0.01% 1803
2014
Q1 		$808 Sell
50,227
-438
-0.9% -$7.49K ﹤0.01% 1773
2013
Q4 		$473 Sell
50,665
-1,104
-2% -$10.8K ﹤0.01% 2094
2013
Q3 		$586 Sell
51,769
-1,574
-3% -$21.6K ﹤0.01% 1894
2013
Q2 		$714K Buy
+53,343
New +$655K ﹤0.01% 1656

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s NBIX Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Neurocrine Biosciences (NBIX) stake by 6.4% in Q2 2026, selling an estimated $642K and leaving 63,784 shares worth $10.7M. The position accounts for 0.01% of the portfolio, ranked #863.

Manulife (Manufacturers Life Insurance) first reported a position in NBIX in Q2 2013 and has held it in 48 quarters since. The position peaked at $17.3M in Q2 2024. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) held 63,784 shares of Neurocrine Biosciences worth $10.7M as of Q2 2026.
  • Manulife (Manufacturers Life Insurance) sold 4,328 Neurocrine Biosciences shares in Q2 2026, an estimated $642K.
  • Neurocrine Biosciences made up 0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #863 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 48 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Neurocrine Biosciences position peaked at $17.3M in Q2 2024.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.